Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases
- 1 April 1992
- journal article
- research article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 184 (1), 80-85
- https://doi.org/10.1016/0006-291x(92)91160-r
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Fission yeast genes that confer resistance to staurosporine encode an AP-1-like transcription factor and a protein kinase related to the mammalian ERK1/MAP2 and budding yeast FUS3 and KSS1 kinases.Genes & Development, 1991
- The FT210 cell line is a mouse G2 phase mutant with a temperature-sensitive CDC2 gene productCell, 1990
- Staurosporine inhibits a tyrosine protein kinase in human hepatoma cell membranesBiochemical and Biophysical Research Communications, 1990
- Staurosporine induces dissolution of microfilament bundles by a protein kinase C-independent pathwayExperimental Cell Research, 1990
- Universal control mechanism regulating onset of M-phaseNature, 1990
- Regulation of p34cdc2 protein kinase during mitosisCell, 1989
- Differential inhibition by staurosporine, a potent protein kinase C inhibitior, of 12-O-tetradecanoylphorbol-13-acetate-caused skin tumor promotion, epidermal ornithine decarboxylase induction, hyperplasia and inflammationCarcinogenesis: Integrative Cancer Research, 1989
- The antiproliferative effects of staurosporine are not exclusively mediated by inhibition of protein kinase CBiochemical and Biophysical Research Communications, 1988
- Staurosporine, a potent protein kinase C inhibitor, fails to inhibit 12-O-tetradecanoylphorbol-13-acetate-caused ornithine decarboxylase induction in isolated mouse epidermal cellsBiochemical and Biophysical Research Communications, 1987
- Staurosporine, a potent inhibitor of phospholipidCa++dependent protein kinaseBiochemical and Biophysical Research Communications, 1986